NEW YORK (GenomeWeb News) – Luminex yesterday reported a 55 percent increase in third-quarter revenues, driven by robust sales of its flagship xMAP technology.
Total revenues for the three months ended Sept. 30 rose to $19.4 million from $12.5 million in the third quarter of 2006.
The quarter’s results included revenue from Tm Bioscience, which Luminex acquired in March and renamed Luminex Molecular Diagnostics.